Takeda gets MHRA nod on Zafatek; Chinese drug MIL-77 used to cure British Ebola patient

> Takeda receives MHRA approval for Type 2 Diabetes' NDA, Zafatek. Release

> Chugai Pharma announce positive Phase III trial results for CT-064 ibandronate oral formulation. Release

> New Abilify formulation approved for Otsuka in Japan. Release

> Australia-based Phylogica said a pilot study for its cell-penetrating peptides showed the ability to destroy drug-resistant breast cancer cells in vivo in tandem with cancer drug Omomyc. Release

> Chinese drug MIL-77 used to cure British Ebola patient. Report

> Abbott Laboratories ($ABT) finds a home in Singapore for $24 million research development center and trial-product factory. Release

> RAPS release Asian Harmonization playbook. Release

> China Pharma's revenue falls 24% to $24.9 million in fiscal year 2014. Report